Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Shyama Computronics and Servic · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Shyama Computronics and Servic
BSE: 531219
BSE: 531219
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Shyama Computronics and Servic
StateQ1 FY27 filed
Last close · 26 Oct 2026₹3.66
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA30.5 · 0.36 · 25.2
Shyama Computronics and Servic is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | (0) | (1) | (0) | (0) | 0 |
| margin % | (79.3) | (556.0) | (23.7) | (4.3) | 18.8 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 0.04 | 0.10 | 0.11 | 0.00 | 0.11 |
| ROE % · ROCE % | 0.4 · 0.5 | 1.0 · 1.5 | 1.1 · 1.3 | 1.4 · 1.7 | 1.1 · 1.5 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (0) | (2) | 0 | (0) | (0) |
| Capex | 0 | 0 | 0 | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Shyama Computronics and Servic · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.02 | 0.02 | 0.00 | 0.02 | 0.05 | 0.04 | 0.02 | 0.01 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 30.5 | 30.1 | 80 of 158 | 50% |
| P/B | 0.4 | 3.0 | 6 of 163 | 97% |
| ROCE | 1.5 | 10.8 | 144 of 183 | 21% |
| ROE | 1.1 | 9.8 | 136 of 166 | 18% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| EBITDA margin | 11.2 | 17.5 | 116 of 165 | 30% |
| Revenue growth | 8.7 | 16.3 | 99 of 161 | 39% |
| Profit growth | (49.2) | 30.9 | 133 of 158 | 16% |
| Market cap | 4 | 810 | 181 of 181 | 0% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Shyama Computronics and Servic · 28 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 13 Oct 2026 · RTA certificate under SEBI Regulation 74(5) filed with BSE for Sept 2026 quarter | compliance | minimal | — | — |
| 28 Sept 2026 · Clarification on alleged delay in AGM proceedings filing | regulatory legal | medium | — | — |
| 23 Sept 2026 · Trading window closes Oct 1 for Q2 FY26 results | compliance | minimal | — | — |
| 2 Sept 2026 · Newspaper publication notice for 29th AGM | compliance | minimal | — | — |
| 1 Sept 2026 · Annual Report for FY 2025-26 submitted to BSE | compliance | minimal | — | — |
| 1 Sept 2026 · Notice of 29th AGM on 23 Sep 2026 via VC; appoints Whole-time Director and CFO | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Newspaper publication of Q1 FY27 and FY26 financial results | compliance | minimal | — | — |
| 10 Aug 2026 · CFO Swaraj Kumar Singh resigns; Roshni Poddar appointed as new WTD and CFO | management changes | high | — | — |
| 10 Aug 2026 · New CFO appointed; old CFO resigns at Shyama Computronics | management changes | high | — | — |
| 10 Aug 2026 · WTD and CFO resigns; new CFO appointed; Q1 results approved | management changes | high | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in